12 June 2019 - Korean patients with severe atopic dermatitis gathered in front of the National Assembly on Tuesday to demand a faster proceeding to allow health insurance coverage for Sanofi’s biological agent Dupixent (dupilumab).

The Association of Patients with Severe Atopic Dermatitis met with Rep. Lee Myoung-su, head of the National Assembly's Health and Welfare Committee, and officials of the Health Insurance Review and Assessment Service (HIRA) to push for the Dupixent reimbursement. 

The patients also staged one-person protests in front of the National Assembly.

Read Korean Biomedical Review article